KH631 gene therapy

· Chengdu Origen Biotechnology Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for KH631 gene therapy, covering 2024-11-27 to 2024-11-27. Get the full timeline:

Most recent: Clinical Trial Update: Safety and Tolerability of KH631 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD) [Phase 1, Phase 2]

See pricing